论文信息 - Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. - 字舞流文

Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.

P. Stephens | J. Ross | D. Lipson | V. Miller | Hong Wu | Siraj M. Ali | M. Cristofanilli | G. Palmer | J. Buell | J. Yu | J. Yu | R. K. Alpaugh | C. Hiemstra | J. Ross